BioXcel extends debt repayment deadline to Aug 21, 2026; liquidity covenant cut to $3M

BioXcel Therapeutics, Inc.

Twelfth Amendment to Credit Agreement with Oaktree dated Aug 10, 2026 extends acceptable transaction deadline from Aug 10 to Aug 21, 2026.
Minimum liquidity covenant reduced to $3.0M from $6.25M effective Aug 10, 2026.
Deadline requires definitive agreements for full repayment or alternative capital solution acceptable to Majority Lenders.
Security Agreement amended to add three commercial tort claims as collateral (Cognitive Research, Caitlin Meyer, Segal Institute).
All other Credit Agreement terms remain in full force; amendment does not waive lender rights.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.